(Q58161174)

2

object named as

Evan Wood

0 references

Thomas Kerr

5

object named as

Thomas Kerr

0 references

author name string

Will Small

1

0 references

Glenn Betteridge

Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5").

3

0 references

publication date

June 2009

0 references

published in

AIDS Care

0 references

volume

21

0 references

issue

6

0 references

page(s)

708-714

0 references

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Trust and the acceptance of and adherence to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Determinants of HAART discontinuation among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Intricacies and inter-relationships between HIV disclosure and HAART: a qualitative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Zidovudine adherence among individuals with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Antiretroviral treatment in correctional facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Incarceration, addiction and harm reduction: inmates experience injecting drugs in prison

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Barriers to use of free antiretroviral therapy in injection drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Adherence in antiretroviral therapy: a review of qualitative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869

Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09540120802511869